Peer-reviewed veterinary case report
Botulinum toxin injection to treat enlarged prostate in dogs
By Mostachio, Giuliano Queiroz et al.·Published in Animal reproduction science·2012·Department of Animal Reproduction, Brazil·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Intra-prostatic injection of botulinum toxin type A in treatment of dogs with spontaneous benign prostatic hyperplasia.
- Species:
- dog
Plain-English summary
Eight male dogs with benign prostatic hyperplasia (BPH), a common condition that can cause symptoms like blood in urine or difficulty urinating, were treated with botulinum toxin type A (BT-A) injections directly into the prostate. The injections were done under ultrasound guidance, and while the prostate size did not significantly decrease after treatment, the dogs did not experience any side effects. Their sexual function remained normal, and the quality of their semen was unaffected. This suggests that while BT-A may not reduce prostate size, it is safe for dogs with BPH.
People also search for: dog blood in urine treatment · benign prostatic hyperplasia in dogs · botulinum toxin for dog prostate issues
Abstract
Benign prostatic hyperplasia (BPH) is a common, naturally developing, age-related condition in dogs. The pathogenesis of BPH is not completely known; however, DHT is a hormone involved in enlargement of the prostate. Recently, the effect of botulinum toxin A (BT-A) was investigated in the rat and human prostate and has shown to induce atrophy of the gland on the canine prostate. This study investigated the effect of BT-A in the canine prostate and on the semen. Eight sexually intact male dogs with BPH (detected radiographically and ultrasonographically), and with clinical signs of BPH (e.g. hematuria or tenesmus) were used. Each lobe of the prostate received an injection of 125 U of BT-A with one-needle pass under transabdominal ultrasound guidance. The clinical results were evaluated at baseline and after treatment. No local complications or systemic adverse effects were reported. At 4 weeks, the mean prostate volume (PV) was not significantly changed after BT-A (from 17.70 ± 6.34 to 16.48 ± 5.98 cm(3)). At 8 weeks the PV had further decreased to 16.04 ± 5.80 cm(3), reaching its maximum effect, but that change was not significant. The results were maintained at 16 weeks. All dogs had normal libido, erection, and ejaculation during semen collection. No significant difference was observed in all seminal parameters. Results suggest that the administration of 250 U of BT-A do not contribute to PV reduction and do not adversely affect the semen quality of dogs with BPH.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/22819377/